A phase II study of lenvatinib a multi-targeted tyrosine kinase inhibitor combined with pembrolizumab (PD-1 inhibitor) for the treatment of metastatic gastroesophageal cancer patients who have progressed on first or subsequent line therapies
If you are registered as a volunteer, please login to the dashboard to send referrals.